| Product Code: ETC7548790 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Dhaval Chaurasia | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 India Neuroblastoma Drug Market Overview |
3.1 India Country Macro Economic Indicators |
3.2 India Neuroblastoma Drug Market Revenues & Volume, 2021 & 2031F |
3.3 India Neuroblastoma Drug Market - Industry Life Cycle |
3.4 India Neuroblastoma Drug Market - Porter's Five Forces |
3.5 India Neuroblastoma Drug Market Revenues & Volume Share, By Mechanism of Action Type, 2021 & 2031F |
3.6 India Neuroblastoma Drug Market Revenues & Volume Share, By Drug Type, 2021 & 2031F |
3.7 India Neuroblastoma Drug Market Revenues & Volume Share, By Diagnosis Type, 2021 & 2031F |
3.8 India Neuroblastoma Drug Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.9 India Neuroblastoma Drug Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 India Neuroblastoma Drug Market Revenues & Volume Share, By End- Users, 2021 & 2031F |
4 India Neuroblastoma Drug Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing incidence of neuroblastoma cases in India |
4.2.2 Advances in medical research leading to the development of new neuroblastoma drugs |
4.3 Market Restraints |
4.3.1 High cost of neuroblastoma drugs limiting accessibility for patients |
4.3.2 Stringent regulatory requirements for drug approval in India |
5 India Neuroblastoma Drug Market Trends |
6 India Neuroblastoma Drug Market, By Types |
6.1 India Neuroblastoma Drug Market, By Mechanism of Action Type |
6.1.1 Overview and Analysis |
6.1.2 India Neuroblastoma Drug Market Revenues & Volume, By Mechanism of Action Type, 2021- 2031F |
6.1.3 India Neuroblastoma Drug Market Revenues & Volume, By Alkylating agents, 2021- 2031F |
6.1.4 India Neuroblastoma Drug Market Revenues & Volume, By Antimetabolites, 2021- 2031F |
6.1.5 India Neuroblastoma Drug Market Revenues & Volume, By Antibiotics, 2021- 2031F |
6.1.6 India Neuroblastoma Drug Market Revenues & Volume, By Microtubule Inhibitors, 2021- 2031F |
6.1.7 India Neuroblastoma Drug Market Revenues & Volume, By Monoclonal Antibodies, 2021- 2031F |
6.2 India Neuroblastoma Drug Market, By Drug Type |
6.2.1 Overview and Analysis |
6.2.2 India Neuroblastoma Drug Market Revenues & Volume, By Cyclophosphamide, 2021- 2031F |
6.2.3 India Neuroblastoma Drug Market Revenues & Volume, By Cisplatin, 2021- 2031F |
6.2.4 India Neuroblastoma Drug Market Revenues & Volume, By Vincristine, 2021- 2031F |
6.2.5 India Neuroblastoma Drug Market Revenues & Volume, By Doxorubicin, 2021- 2031F |
6.2.6 India Neuroblastoma Drug Market Revenues & Volume, By Etoposide, 2021- 2031F |
6.2.7 India Neuroblastoma Drug Market Revenues & Volume, By Topotecan, 2021- 2031F |
6.3 India Neuroblastoma Drug Market, By Diagnosis Type |
6.3.1 Overview and Analysis |
6.3.2 India Neuroblastoma Drug Market Revenues & Volume, By Physical Test, 2021- 2031F |
6.3.3 India Neuroblastoma Drug Market Revenues & Volume, By Urine and Blood Test, 2021- 2031F |
6.3.4 India Neuroblastoma Drug Market Revenues & Volume, By Imaging Test, 2021- 2031F |
6.3.5 India Neuroblastoma Drug Market Revenues & Volume, By Tissue Sample Testing, 2021- 2031F |
6.3.6 India Neuroblastoma Drug Market Revenues & Volume, By Bone Marrow Sample Testing, 2021- 2031F |
6.4 India Neuroblastoma Drug Market, By Treatment Type |
6.4.1 Overview and Analysis |
6.4.2 India Neuroblastoma Drug Market Revenues & Volume, By Surgery, 2021- 2031F |
6.4.3 India Neuroblastoma Drug Market Revenues & Volume, By Chemotherapy, 2021- 2031F |
6.4.4 India Neuroblastoma Drug Market Revenues & Volume, By Radiotherapy, 2021- 2031F |
6.4.5 India Neuroblastoma Drug Market Revenues & Volume, By Immunotherapy, 2021- 2031F |
6.4.6 India Neuroblastoma Drug Market Revenues & Volume, By Bone Marrow transplantation, 2021- 2031F |
6.4.7 India Neuroblastoma Drug Market Revenues & Volume, By Retinoid Therapy, 2021- 2031F |
6.5 India Neuroblastoma Drug Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 India Neuroblastoma Drug Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 India Neuroblastoma Drug Market Revenues & Volume, By Intravenous and others, 2021- 2031F |
6.6 India Neuroblastoma Drug Market, By End- Users |
6.6.1 Overview and Analysis |
6.6.2 India Neuroblastoma Drug Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 India Neuroblastoma Drug Market Revenues & Volume, By Homecare, 2021- 2031F |
6.6.4 India Neuroblastoma Drug Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.6.5 India Neuroblastoma Drug Market Revenues & Volume, By Others, 2021- 2031F |
7 India Neuroblastoma Drug Market Import-Export Trade Statistics |
7.1 India Neuroblastoma Drug Market Export to Major Countries |
7.2 India Neuroblastoma Drug Market Imports from Major Countries |
8 India Neuroblastoma Drug Market Key Performance Indicators |
8.1 Percentage of patients receiving timely diagnosis and treatment |
8.2 Adoption rate of innovative treatment options in neuroblastoma |
8.3 Number of clinical trials for neuroblastoma drugs in India |
9 India Neuroblastoma Drug Market - Opportunity Assessment |
9.1 India Neuroblastoma Drug Market Opportunity Assessment, By Mechanism of Action Type, 2021 & 2031F |
9.2 India Neuroblastoma Drug Market Opportunity Assessment, By Drug Type, 2021 & 2031F |
9.3 India Neuroblastoma Drug Market Opportunity Assessment, By Diagnosis Type, 2021 & 2031F |
9.4 India Neuroblastoma Drug Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.5 India Neuroblastoma Drug Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 India Neuroblastoma Drug Market Opportunity Assessment, By End- Users, 2021 & 2031F |
10 India Neuroblastoma Drug Market - Competitive Landscape |
10.1 India Neuroblastoma Drug Market Revenue Share, By Companies, 2024 |
10.2 India Neuroblastoma Drug Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here